RGEN earnings analysis
What we found in RGEN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Repligen's Q1 2026 results showed a strong performance with revenue of $194.3 million, marking a 14.8% YoY increase, and an EPS of $0.48, surpassing estimates of $0.38. The company's growth was driven by robust product sales across segments, particularly in the chromatography and analytics sectors, demonstrating effective market penetration and operational efficiency.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 14.8% YoY
- Q1 2026 revenue reached $194.25 million, up from $169.17 million in Q1 2025.
- EPS Surpasses Expectations
- Repligen reported an EPS of $0.48, beating estimates of $0.38 and increasing from $0.10 in Q1 2025.
- Improved Gross Margin
- Gross margin improved to 55.7%, up from 54.0% YoY, due to favorable sales mix and improved efficiency.
- Significant Revenue Contribution from Acquisitions
- Revenue from the 908 Devices PAT Portfolio contributed $2.4 million.
- Positive Operating Cash Flow
- Operating cash flow for Q1 2026 increased to $28.3 million, up from $15.0 million in Q1 2025.
- Increase in Liquidity
- Cash and cash equivalents rose to $582.65 million from $566.02 million at the end of 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Loss on Sale of Business
- Repligen recognized a significant loss of $13.8 million from the sale of Polymem S.A.S.
- Increased Interest Expense
- Interest expense rose to $5.58 million from $5.25 million, reflecting higher debt costs.
- Material Weaknesses in Internal Control
- The company reported ongoing material weaknesses in internal control over financial reporting.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.48
- Gross margin
- 55.7%
- Segment
- Filtration products: $95.84M
- Segment
- Chromatography products: $41.14M
- Segment
- Process analytics products: $23.56M
- Segment
- Proteins products: $32.80M
What they said about what is next.
Management expects 2026 revenue between $803 million and $833 million and EPS between $1.97 and $2.05, with a focus on continued product innovation.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Repligen reported a recovery in profitability through 2025 with Q4 revenue of $197,913,000 and improving margins (Q4 2025 gross margin 52.5%, operating margin 9.0%) after a weak Q4 2024. The company is executing a…
- 10-Q · August 7, 2025
- Repligen reported a strong Q2 2025 quarter with revenue of $182,366,000 (Q2 2024: $158,839,000), driving operating income of $13,896,000 (Q2 2024: $5,469,000) and diluted EPS of $0.26 (Q2 2024: $0.10). Management…
- 10-Q · April 29, 2025
- Repligen reported a stronger Q1 2025 with revenue rising to $169.172M from $153.182M a year ago (+$15.99M, +10.4%), gross margin expanding to ~53.7% (COGS $78.415M) and operating income rising to $6.578M (3.9% op…
- 10-K · March 14, 2025
- Repligen positions itself as a diversified bioprocessing platform selling consumables, systems and analytics across four franchises (Filtration; Chromatography; Process Analytics; Proteins) and is shifting from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RGEN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever